Ustekinumab is indicated for the management of moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults and children 6 years or older who are candidates for phototherapy or systemic therapy. It is in a class of medications called monoclonal antibodies. Ustekinumab is used alone or in combination with methotrexate (rasuvo, otrexup, trexall) to treat psoriatic arthritis in adults. Psoriatic arthritis is a condition that causes joint pain and swelling and scales on the skin. Moreover, it is also used to treat Crohn's disease and ulcerative colitis. However, Crohn's disease is a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever. Ustekinumab works by stopping the action of certain cells in the body that cause the symptoms of psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn's disease. Common side effects include nausea, headache, tiredness runny, stuffed nose, or sneezing, and joint pain. Furthermore, other serious side effects include seizures, vision changes, difficulty in breathing, and others.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the ustekinumab market.
Top Impacting Factors
- Rise in prevalence of psoriasis patients across the globe drives the growth of the ustekinumab market.
- In addition, changes in lifestyles, increase in inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people prone to this condition (psoriasis), which further influences the market growth.
- Furthermore, continuous economic development with developing healthcare infrastructure and improving healthcare awareness have been further supporting the market growth.
- On the contrary, rise in awareness about the prevention and treatment of psoriasis and increase in investments in R&D activities to develop novel treatment for psoriasis are expected to offer lucrative growth opportunities for the expansion of the market during the forecast period.
- However, adverse effects of ustekinumab such as seizures, vision changes, and difficulty in breathing is expected to hamper the growth of the market.
Market Trends
New Product Launches to Flourish the Market
In February 2019, Janssen Biotech Inc., a biotechnology company, received the United States Food and Drug Administration approved TREMFYA for the treatment of severe plaque psoriasis.
In July 2020, Fujifilm Kyowa Kirin Biologics received the Japanese regulatory approval for manufacturing and marketing of the first adalimumab biosimilar in the island country for the indication of psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-behcet's disease, and Crohn's disease.
In August 2020, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto after receiving marketing authorization from the European Commission in May 2020 for indications, including psoriatic arthritis and plaque psoriasis.
Key Benefits of the Report
- This study presents the analytical depiction of the ustekinumab market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Ustekinumab Market Report
- Which are the leading market players active in the ustekinumab market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is ustekinumab market?
- What is ustekinumab market prediction in the future?
- Who are the leading global players in the ustekinumab market?
- What are the current trends and predicted trends?
- What are the key benefits of the ustekinumab market report?
Ustekinumab Market, by Dosage Form Report Highlights
| Aspects | Details |
 By Dosage Form |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | NeuClone, Alvotech, Formycon, Mitsubishi Tanabe, Johnson and Johnson, EPIRUS BioPharma, Meiji, Outlook Therapeutics, Stada, Fuji Pharma |
Loading Table Of Content...
